Intravesical therapy for bladder cancer

Steve K. Williams, David M. Hoenig, Reza Ghavamian, Mark Soloway

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Importance of the field: Although transurethral resection of bladder tumor (TURBT) is effective therapy, up to 45% of patients will have a recurrence within 1 year after TURBT alone. Further, there is a 3 15% risk of tumor progression to muscle invasive and/or metastatic cancer. Depending on patient and tumor characteristics, a number of patients may benefit from some form of intravesical therapy. Adjuvant therapy is effective in avoiding post-TURBT implantation of tumor cells, eradicating residual disease, preventing tumor recurrence, and to delay or reduce tumor progression through direct cytoablation or immunostimulation. Areas covered in this review: The role of risk assessment in the management of nonmuscle invasive bladder cancer (NMIBC) and the indications for the use of intravesical agents are discussed. Findings from major randomized clinical trials on BCG, interferon and various chemotherapeutic agents are summarized; key aspects of drug pharmacology, drug efficacy, side effects, and toxicity are also covered. What the reader will gain: The reader will gain a basic understanding of the role of risk assessment in determining the need for intravesical therapy, as well as an overview of the different types of agents in use in the United States today. Take home message: The type of intravesical therapy used is based on the risk groups as noted in the European prognostic tables. Bacillus CalmetteGuerin (BCG) is the most commonly used first-line agent immunotherapeutic agent for prophylaxis and treatment of carcinoma in situ and high-grade bladder cancer. Other immunotherapeutic options include the interferons, interleukins 2 and 12, and tumor necrosis factor, all of which have activity in BCG refractory patients, although with low durable remission rates. Studies have shown that chemotherapy prevents recurrence but not progression. The available data on intravesical chemotherapy do not indicate that any single agent currently in use is clearly better than any other. Therefore, the selection of a chemotherapeutic agent is usually based on cost, toxicity, and availability as well as on physician preference and experience.

Original languageEnglish (US)
Pages (from-to)947-958
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number6
DOIs
StatePublished - Apr 2010

Fingerprint

Urinary Bladder Neoplasms
Bacillus
Neoplasms
Recurrence
Interferons
Therapeutics
Drug Therapy
Carcinoma in Situ
Interleukin-12
Drug-Related Side Effects and Adverse Reactions
Interleukin-2
Immunization
Randomized Controlled Trials
Tumor Necrosis Factor-alpha
Pharmacology
Physicians
Costs and Cost Analysis
Muscles
Pharmaceutical Preparations

Keywords

  • BCG
  • Bladder cancer
  • Intravesical therapy
  • Mitomicin
  • Nonmuscle invasive bladder cancer
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Williams, S. K., Hoenig, D. M., Ghavamian, R., & Soloway, M. (2010). Intravesical therapy for bladder cancer. Expert Opinion on Pharmacotherapy, 11(6), 947-958. https://doi.org/10.1517/14656561003657145

Intravesical therapy for bladder cancer. / Williams, Steve K.; Hoenig, David M.; Ghavamian, Reza; Soloway, Mark.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 6, 04.2010, p. 947-958.

Research output: Contribution to journalArticle

Williams, SK, Hoenig, DM, Ghavamian, R & Soloway, M 2010, 'Intravesical therapy for bladder cancer', Expert Opinion on Pharmacotherapy, vol. 11, no. 6, pp. 947-958. https://doi.org/10.1517/14656561003657145
Williams SK, Hoenig DM, Ghavamian R, Soloway M. Intravesical therapy for bladder cancer. Expert Opinion on Pharmacotherapy. 2010 Apr;11(6):947-958. https://doi.org/10.1517/14656561003657145
Williams, Steve K. ; Hoenig, David M. ; Ghavamian, Reza ; Soloway, Mark. / Intravesical therapy for bladder cancer. In: Expert Opinion on Pharmacotherapy. 2010 ; Vol. 11, No. 6. pp. 947-958.
@article{303f81d4f5504f55ab582698d9594e2d,
title = "Intravesical therapy for bladder cancer",
abstract = "Importance of the field: Although transurethral resection of bladder tumor (TURBT) is effective therapy, up to 45{\%} of patients will have a recurrence within 1 year after TURBT alone. Further, there is a 3 15{\%} risk of tumor progression to muscle invasive and/or metastatic cancer. Depending on patient and tumor characteristics, a number of patients may benefit from some form of intravesical therapy. Adjuvant therapy is effective in avoiding post-TURBT implantation of tumor cells, eradicating residual disease, preventing tumor recurrence, and to delay or reduce tumor progression through direct cytoablation or immunostimulation. Areas covered in this review: The role of risk assessment in the management of nonmuscle invasive bladder cancer (NMIBC) and the indications for the use of intravesical agents are discussed. Findings from major randomized clinical trials on BCG, interferon and various chemotherapeutic agents are summarized; key aspects of drug pharmacology, drug efficacy, side effects, and toxicity are also covered. What the reader will gain: The reader will gain a basic understanding of the role of risk assessment in determining the need for intravesical therapy, as well as an overview of the different types of agents in use in the United States today. Take home message: The type of intravesical therapy used is based on the risk groups as noted in the European prognostic tables. Bacillus CalmetteGuerin (BCG) is the most commonly used first-line agent immunotherapeutic agent for prophylaxis and treatment of carcinoma in situ and high-grade bladder cancer. Other immunotherapeutic options include the interferons, interleukins 2 and 12, and tumor necrosis factor, all of which have activity in BCG refractory patients, although with low durable remission rates. Studies have shown that chemotherapy prevents recurrence but not progression. The available data on intravesical chemotherapy do not indicate that any single agent currently in use is clearly better than any other. Therefore, the selection of a chemotherapeutic agent is usually based on cost, toxicity, and availability as well as on physician preference and experience.",
keywords = "BCG, Bladder cancer, Intravesical therapy, Mitomicin, Nonmuscle invasive bladder cancer, Urothelial carcinoma",
author = "Williams, {Steve K.} and Hoenig, {David M.} and Reza Ghavamian and Mark Soloway",
year = "2010",
month = "4",
doi = "10.1517/14656561003657145",
language = "English (US)",
volume = "11",
pages = "947--958",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Intravesical therapy for bladder cancer

AU - Williams, Steve K.

AU - Hoenig, David M.

AU - Ghavamian, Reza

AU - Soloway, Mark

PY - 2010/4

Y1 - 2010/4

N2 - Importance of the field: Although transurethral resection of bladder tumor (TURBT) is effective therapy, up to 45% of patients will have a recurrence within 1 year after TURBT alone. Further, there is a 3 15% risk of tumor progression to muscle invasive and/or metastatic cancer. Depending on patient and tumor characteristics, a number of patients may benefit from some form of intravesical therapy. Adjuvant therapy is effective in avoiding post-TURBT implantation of tumor cells, eradicating residual disease, preventing tumor recurrence, and to delay or reduce tumor progression through direct cytoablation or immunostimulation. Areas covered in this review: The role of risk assessment in the management of nonmuscle invasive bladder cancer (NMIBC) and the indications for the use of intravesical agents are discussed. Findings from major randomized clinical trials on BCG, interferon and various chemotherapeutic agents are summarized; key aspects of drug pharmacology, drug efficacy, side effects, and toxicity are also covered. What the reader will gain: The reader will gain a basic understanding of the role of risk assessment in determining the need for intravesical therapy, as well as an overview of the different types of agents in use in the United States today. Take home message: The type of intravesical therapy used is based on the risk groups as noted in the European prognostic tables. Bacillus CalmetteGuerin (BCG) is the most commonly used first-line agent immunotherapeutic agent for prophylaxis and treatment of carcinoma in situ and high-grade bladder cancer. Other immunotherapeutic options include the interferons, interleukins 2 and 12, and tumor necrosis factor, all of which have activity in BCG refractory patients, although with low durable remission rates. Studies have shown that chemotherapy prevents recurrence but not progression. The available data on intravesical chemotherapy do not indicate that any single agent currently in use is clearly better than any other. Therefore, the selection of a chemotherapeutic agent is usually based on cost, toxicity, and availability as well as on physician preference and experience.

AB - Importance of the field: Although transurethral resection of bladder tumor (TURBT) is effective therapy, up to 45% of patients will have a recurrence within 1 year after TURBT alone. Further, there is a 3 15% risk of tumor progression to muscle invasive and/or metastatic cancer. Depending on patient and tumor characteristics, a number of patients may benefit from some form of intravesical therapy. Adjuvant therapy is effective in avoiding post-TURBT implantation of tumor cells, eradicating residual disease, preventing tumor recurrence, and to delay or reduce tumor progression through direct cytoablation or immunostimulation. Areas covered in this review: The role of risk assessment in the management of nonmuscle invasive bladder cancer (NMIBC) and the indications for the use of intravesical agents are discussed. Findings from major randomized clinical trials on BCG, interferon and various chemotherapeutic agents are summarized; key aspects of drug pharmacology, drug efficacy, side effects, and toxicity are also covered. What the reader will gain: The reader will gain a basic understanding of the role of risk assessment in determining the need for intravesical therapy, as well as an overview of the different types of agents in use in the United States today. Take home message: The type of intravesical therapy used is based on the risk groups as noted in the European prognostic tables. Bacillus CalmetteGuerin (BCG) is the most commonly used first-line agent immunotherapeutic agent for prophylaxis and treatment of carcinoma in situ and high-grade bladder cancer. Other immunotherapeutic options include the interferons, interleukins 2 and 12, and tumor necrosis factor, all of which have activity in BCG refractory patients, although with low durable remission rates. Studies have shown that chemotherapy prevents recurrence but not progression. The available data on intravesical chemotherapy do not indicate that any single agent currently in use is clearly better than any other. Therefore, the selection of a chemotherapeutic agent is usually based on cost, toxicity, and availability as well as on physician preference and experience.

KW - BCG

KW - Bladder cancer

KW - Intravesical therapy

KW - Mitomicin

KW - Nonmuscle invasive bladder cancer

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77949905932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949905932&partnerID=8YFLogxK

U2 - 10.1517/14656561003657145

DO - 10.1517/14656561003657145

M3 - Article

C2 - 20205607

AN - SCOPUS:77949905932

VL - 11

SP - 947

EP - 958

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -